Imidazoles as potential anticancer agents: An update on recent studies

P Sharma, C LaRosa, J Antwi, R Govindarajan… - Molecules, 2021 - mdpi.com
Nitrogen-containing heterocyclic rings are common structural components of marketed
drugs. Among these heterocycles, imidazole/fused imidazole rings are present in a wide …

Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development

J Liu, C Chen, D Wang, J Zhang, T Zhang - European journal of medicinal …, 2021 - Elsevier
Therapy based on Bruton's tyrosine kinase (BTK) inhibitors one of the major treatment
options currently recommended for lymphoma patients. The first generation of BTK inhibitor …

Progress in the development of small molecular inhibitors of the Bruton's tyrosine kinase (BTK) as a promising cancer therapy

XJ Liu, XJ Pang, XY Yuan, GX Yu, YR Li… - Bioorganic & medicinal …, 2021 - Elsevier
Bruton tyrosine kinase (BTK) is a key kinase in the B cell antigen receptor signal
transduction pathway, which is involved in the regulation of the proliferation, differentiation …

An insight into the rational design of recent purine-based scaffolds in targeting various cancer pathways

A Chaurasiya, SK Wahan, C Sahu… - Journal of Molecular …, 2023 - Elsevier
Impacting the lives of millions throughout the globe, cancer is the world's leading cause of
death. In cancer treatment and prognosis, a number of anticancer medicines have been …

Recent research of BTK inhibitors: Methods of structural design, pharmacological activities, manmade derivatives and structure–activity relationship

L Wang, Z Zhang, D Yu, L Yang, L Li, Y He, J Shi - Bioorganic Chemistry, 2023 - Elsevier
Protein kinases constitute the largest group within the kinase family, and mutations and
translocations of protein kinases due to genetic alterations are intimately linked to the …

Design, Synthesis, In Silico Studies and Inhibitory Activity towards Bcr-Abl, BTK and FLT3-ITD of New 2, 6, 9-Trisubstituted Purine Derivatives as Potential Agents for …

J Bertrand, H Dostálová, V Kryštof, R Jorda, T Delgado… - Pharmaceutics, 2022 - mdpi.com
We report 31 new compounds designed, synthesized and evaluated on Bcr-Abl, BTK and
FLT3-ITD as part of our program to develop 2, 6, 9-trisubstituted purine derivatives as …

The Progress of Small Molecule Targeting BCR-ABL in the Treatment of Chronic Myeloid Leukemia

Y Zhang, X Wu, X Sun, J Yang, C Liu… - Mini Reviews in …, 2024 - ingentaconnect.com
Chronic myelogenous leukemia (CML) is a malignant myeloproliferative disease. According
to the American Cancer Society's 2021 cancer data report, new cases of CML account for …

New Smoothened ligands based on the purine scaffold as potential agents for treating pancreatic cancer

C Espinosa-Bustos, J Bertrand, A Villegas-Menares… - Bioorganic …, 2024 - Elsevier
Aberrant activation of the Hedgehog (Hh) signalling pathway has been associated with the
development and progression of pancreatic cancer. For this reason, blockade of Hh pathway …

Synthesis, antitumoral activity, and in silico studies on Smoothened receptor of new 2, 6, 9-trisubstituted purine derivatives

C Espinosa-Bustos, AM Zárate, A Castro-Álvarez… - Journal of Molecular …, 2025 - Elsevier
In this work, a series of 30 new 2, 6, 9-trisubstituted purine derivatives were synthesised and
evaluated in silico as potential ligands of the Smoothened (SMO) receptor, as well as their …

A facile approach to [1, 2, 4] triazolo [3, 4‐i] purine via PIDA oxidation ring‐closing reaction

X Sun, M Yu, X Mu, Z Zhou, L Wang… - Journal of Heterocyclic …, 2021 - Wiley Online Library
Abstract A facile conversion of 6‐(2‐arylidenehydrazineyl) purines to [1, 2, 4] triazolo [3, 4‐i]
purines is presented using PhI (OAc) 2 as oxidant in only 10 min under room temperature …